Lawsuit over migraine deal could be good for Amgen, analysts say

Novartis AG and Amgen Inc. filed dueling lawsuits on Thursday over a deal the two companies made to jointly develop and market a migraine drug, Aimovig, that could one day bring in billions of dollars in revenue.